PDCD1 and Cirrhosis: Anti‐PD‐1 therapy has yet to be tested in an ACLF group, but given that lymphocytes from patients with decompensated cirrhosis and acute alcoholic hepatitis show a higher expression of PD‐1 compared to compensated cirrhosis or healthy controls, PD‐1 inhibitors may indeed prove beneficial.34, 109